Anavex Life Sciences Names Terrie Kellmeyer, Ph.D., as President and Chief Executive Officer and Member of the Board of Directors
Key Highlights
- ➤Terrie Kellmeyer appointed Anavex president and CEO, joining the board
- ➤FDA cleared Anavex’s Fragile X syndrome Investigational New Drug application
- ➤Anavex completed key clinical pharmacology studies across its development portfolio
- ➤Anavex continues preparations for its planned Phase 3 Rett syndrome program
Expert Statements
Peter Donhauser, Member of the Board of Directors at Anavex
“Dr. Kellmeyer has provided steady leadership and a clear vision during an important period for Anavex, sharpening the focus of our clinical programs and advancing our engagement with the FDA.”
Peter Donhauser, Member of the Board of Directors at Anavex
“She brings a deep understanding of our science, a disciplined approach to execution and an unwavering commitment to patients.”
Peter Donhauser, Member of the Board of Directors at Anavex
“The Board’s decision reflects our unequivocal support for her strategy and her plans to build a top-notch management team, and we are confident she is the ideal leader to drive Anavex to its full potential.”
Terrie Kellmeyer, President and Chief Executive Officer of Anavex
“I am honored by the Board’s confidence and grateful to our team, whose dedication over the past several months has positioned Anavex for its next chapter.”
Terrie Kellmeyer, President and Chief Executive Officer of Anavex
“We have strengthened our operations, advanced each of our programs and established a constructive dialogue with the FDA.”
Terrie Kellmeyer, President and Chief Executive Officer of Anavex
“My priorities are clear: disciplined execution of our clinical plans, generating high-quality data to support regulatory decisions and transparent communication with patients, investors and regulators.”
Terrie Kellmeyer, President and Chief Executive Officer of Anavex
“We are accountable to the patients and families we serve and to our shareholders, and we intend to deliver on our commitments.”
NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Nasdaq: AVXL) (“Anavex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments for central nervous system diseases with significant unmet medical needs, today announced that on November 1, 2026, its Board of Directors appointed Terrie Kellmeyer, Ph.D., who had been serving as the Company’s Interim Chief Executive Officer, as the Company’s President and Chief Executive Officer. She will also join Anavex’s Board of Directors.
“Dr. Kellmeyer has provided steady leadership and a clear vision during an important period for Anavex, sharpening the focus of our clinical programs and advancing our engagement with the FDA,” said Peter Donhauser, D.O., member of the Board of Directors. “She brings a deep understanding of our science, a disciplined approach to execution and an unwavering commitment to patients. The Board’s decision reflects our unequivocal support for her strategy and her plans to build a top-notch management team, and we are confident she is the ideal leader to drive Anavex to its full potential.”
Get started
Create a free account to read the full story.